Resources

Engineering Access: It All Comes Back to the Patient Experience

Advanced Therapies: Access Is Still the Hard Part

CAR-T Platform Moves Novel Therapies from Gene Sequence to Clinic-ready in Under 12 Months

CAR-T has a geography problem

The Next Cancer Revolution Isn’t Scientific—It’s Manufacturing

Robust Lentiviral Manufacturing Platforms in the Age of Accessible Cell Therapy

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

Bio2Bedside: The Cell Therapy Cost-Reduction Playbook

What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?

What do you see as the biggest threat to the CDMO industry in 2026 or beyond?

Scroll to Top